Windlas Biotech Limited has submitted to the Exchange, the financial results for the period ended Jun 30, 2025.
WINDLAS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Windlas Biotech reported consolidated revenue from operations of ₹2,100.9 million for Q1 FY26, up about 20% from ₹1,751.5 million in Q1 FY25. Total income stood at ₹2,153.3 million versus ₹1,792.9 million in the year-ago quarter. Profit before tax rose to ₹232.6 million (from ₹183.1 million), and profit after tax grew roughly 31% to ₹176.6 million (from ₹134.8 million). Basic EPS came in at ₹8.43 versus ₹6.47 a year earlier. The statutory auditors (J.C. Bhalla & Co.) issued an unmodified limited review conclusion on both standalone and consolidated results. Standalone numbers are broadly in line with consolidated figures, with the company operating in a single Pharmaceuticals segment.
Strong topline and bottomline growth year-on-year, with PAT expanding faster than revenue, which is positive for shareholders. The clean auditor report with no qualifications supports confidence in the numbers, though investors should note that revenue growth was just shy of the 20% mark.